APA (7th ed.) Citation

Hütter-Krönke, M., & Schlenk, R. F. (2019). Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options: Results from a phase I study. Haematologica, 104(2), . https://doi.org/10.3324/haematol.2018.199794

Chicago Style (17th ed.) Citation

Hütter-Krönke, Marie-Luise, and Richard Friedrich Schlenk. "Continuous High Dosing of Lenalidomide in Relapsed, Refractory or Older Newly Diagnosed Acute Myeloid Leukemia Patients Not Suitable for Other Treatment Options: Results from a Phase I Study." Haematologica 104, no. 2 (2019). https://doi.org/10.3324/haematol.2018.199794.

MLA (9th ed.) Citation

Hütter-Krönke, Marie-Luise, and Richard Friedrich Schlenk. "Continuous High Dosing of Lenalidomide in Relapsed, Refractory or Older Newly Diagnosed Acute Myeloid Leukemia Patients Not Suitable for Other Treatment Options: Results from a Phase I Study." Haematologica, vol. 104, no. 2, 2019, https://doi.org/10.3324/haematol.2018.199794.